Join this channel to get access to perks:
/ @drarjunsabharwal
Welcome to our Proteinuria Series! In this video, we dive deep into Membranous Nephropathy—a key cause of high creatinine and kidney damage. We’ll explore new updates in diagnosis and treatment, including heart health risks associated with proteinuria. Learn how to spot early symptoms, manage kidney function, and understand evidence-based therapies like Rituximab, Calcineurin Inhibitors, and Cyclophosphamide.
We also discuss the vital link between protein leakage and cardiovascular disease, along with the latest KDIGO guidelines. If you or someone you know struggles with chronic kidney disease (CKD), high blood pressure, or Nephrotic Syndrome, this video will provide actionable insights to help safeguard both your kidneys and your heart.
Stay tuned for tips on lifestyle modifications, dietary changes, and how to prevent disease progression. Don’t forget to subscribe for more in-depth health content on proteinuria, kidney care, and renal health. If you find this video valuable, please like, share, and leave your questions in the comments—I’ll be answering them in upcoming shorts and detailed episodes!
Links:
KDIGO Guidelines : https://kdigo.org/wp-content/uploads/...
PONTICELLI REGIMEN : https://www.sciencedirect.com/science...
Protein and Heart Health https://pmc.ncbi.nlm.nih.gov/articles...
Timeline:
00:00 Proteinuria series
01:00 Membranous Nephropathy kya hai
03:10 Heart par kya asar hai
04:50 Kaise treatment hota hai
08:00 Monitor kaise karen
Keywords: Membranous Nephropathy, High Creatinine, Proteinuria, Heart Health, KDIGO Guidelines, Nephrotic Syndrome, Kidney Disease, Dialysis, Rituximab, Calcineurin Inhibitors, Cyclophosphamide, Anti-PLA2R, Chronic Kidney Disease, Renal Health, Nephrology, CKD, Cardiovascular Risk, Kidney Care, Health Tips
#MembranousNephropathy #Proteinuria #HighCreatinine #KidneyHealth #HeartHealth #CKD #NephroticSyndrome #KidneyDisease #KidneyCare #KDIGOGuidelines #Rituximab #CalcineurinInhibitors #Cyclophosphamide #RenalHealth #ChronicKidneyDisease #Dialysis #AntiPLA2R #EvidenceBasedMedicine #MedicalEducation #healthtips
My name is Dr Arjun Sabharwal , MBBS , MRCP UK and Nephrology ST and my aim is to create chronic kidney disease awareness in India. I believe prevention is the best cure and as a doctor its my job to provide you with the right information. This channel was also known as living with kidney disease.
So please like , share and Subscribe to the channel.
#CKD treatment in Hindi #kidney disease diet tips #CKD symptoms and prevention
Social Links:
Instagram : / drarjunsabharwal
Facebook : / dr-arjun-sabharwal-nephrology-61555047418729
Twitter (X) : https://x.com/sabharwaldoc?s=21&t=9GF...
--------------------------------------------------------------------------------------------------------------------------------------------
DISCLAIMER
The content provided on this channel by Dr Arjun Sabharwal is for informational purposes only and is not intended as medical advice, or as a substitute for the medical advice of a physician. The information and discussions about kidney disease and related health issues are not intended to diagnose, treat, cure, or prevent any disease. Do not disregard professional medical advice or delay seeking it because of something you have heard or seen on this channel.
The experiences shared here are personal and may not necessarily reflect typical results or outcomes. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition.
Consent : All patients present in the podcasts videos have provided written consent before these videos were uploaded.
All talks, music, and images in this video and on my YouTube channel are the property of "Living with Kidney Disease" by Dr. Arjun Sabharwal. Feel free to share and embed this video on your website or other platforms, provided you include a link back to my YouTube channel - "Dr Arjun Sabharwal - Kidney Doc"
--------------------------------------------------------------------------------------------------------------------------------------------
Информация по комментариям в разработке